Skip main navigation

Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation

Results From the Henry Ford Exercise Testing (FIT) Project
Originally publishedhttps://doi.org/10.1161/CIRCULATIONAHA.114.014833Circulation. 2015;131:1827–1834

Abstract

Background—

Poor cardiorespiratory fitness (CRF) is an independent risk factor for cardiovascular morbidity and mortality. However, the relationship between CRF and atrial fibrillation (AF) is less clear. The aim of this analysis was to investigate the association between CRF and incident AF in a large, multiracial cohort that underwent graded exercise treadmill testing.

Methods and Results—

From 1991 to 2009, a total of 64 561 adults (mean age, 54.5±12.7 years; 46% female; 64% white) without AF underwent exercise treadmill testing at a tertiary care center. Baseline demographic and clinical variables were collected. Incident AF was ascertained by use of International Classification of Diseases, Ninth Revision code 427.31 and confirmed by linkage to medical claim files. Nested, multivariable Cox proportional hazards models were used to estimate the independent association of CRF with incident AF. During a median follow-up of 5.4 years (interquartile range, 3–9 years), 4616 new cases of AF were diagnosed. After adjustment for potential confounders, 1 higher metabolic equivalent achieved during treadmill testing was associated with a 7% lower risk of incident AF (hazard ratio, 0.93; 95% confidence interval, 0.92–0.94; P<0.001). This relationship remained significant after adjustment for incident coronary artery disease (hazard ratio, 0.92; 95% confidence interval, 0.91–0.93; P<0.001). The magnitude of the inverse association between CRF and incident AF was greater among obese compared with nonobese individuals (P for interaction=0.02).

Conclusions—

There is a graded, inverse relationship between cardiorespiratory fitness and incident AF, especially among obese patients. Future studies should examine whether changes in fitness increase or decrease risk of atrial fibrillation. This association was stronger for obese compared with nonobese, especially among obese patients.

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, currently affecting >2 million people in the United States.1 With an aging population, its prevalence is projected to double over the next 30 years.2,3 The total health expenditures incurred by patients with AF are almost 5 times those of patients without AF, ranging between $6 and $26 billion.4 AF is also associated with considerable morbidity and mortality.5 Although the management of AF has received much attention, literature furthering our understanding of AF prevention remains limited.

Editorial see p 1821

Clinical Perspective on p 1834

Several studies have suggested an association between lifetime physical activity and the development of AF.6,7 However, these studies used self–reported physical activity as a measure of physical function, which is not a direct measure of underlying physiology. The impact of cardiorespiratory fitness (CRF) on risk of AF has not been examined previously in large, multiracial cohort. In addition, it is not known if this relationship is influenced by incident coronary artery disease or incident left ventricular dysfunction, and the interactions between modifiable risk factors of AF (including obesity, hypertension, diabetes mellitus, smoking, and hyperlipidemia) and CRF and incident AF are also not well established.

Thus, we aimed to examine the relationship of CRF with the risk of incident AF among a large, multiethnic cohort of individuals undergoing a graded exercise treadmill test.

Methods

Study Population and Settings

The methods of the Henry Ford Exercise Testing (FIT) Project have been published previously.8 In short, the FIT Project is a retrospective cohort study of 69 885 patients who underwent physician-referred treadmill stress testing at affiliated hospitals and clinics across metropolitan Detroit, MI, within the Henry Ford Health System between 1991 and 2009. Data pertaining to exercise parameters, demographics, medications, and medical history were obtained by exercise physiologists and nurses and logged after the exercise test encounter. Patients with known AF (n=1763), heart failure (n=1565), or atrial flutter (n=78) and those with missing data (resting systolic pressure, 521; peak systolic pressure, 190; peak heart rate, 55; metabolic equivalents [METs], 826; total=1592) at the time of the stress test were also excluded from our analysis. The final sample used for the present analysis was 64 561. The FIT Project was approved by the Henry Ford Health System Institutional Review Board.

Graded Exercise Treadmill Testing

All patients underwent clinically indicated, symptom-limited treadmill stress testing following the standard Bruce protocol.9 Individuals who underwent the modified Bruce protocol or other non-Bruce protocols were excluded from the project. Resting heart rate and blood pressure were assessed manually immediately before each test. CRF was calculated by the Quinton treadmill controller on the basis of the elevation and speed achieved by the patient during the test and was expressed in METs. The treadmill speed was set initially at 1.7 mph and then increased to 2.5, 3.3, 4.2, 5.0, and 5.5 mph on minutes 3, 6, 9, 12, and 15, respectively. In the first 3 minutes, the grade was set at 10%, followed by a 2% increase every 3 minutes. The patient exercised for 3 minutes in each stage. Termination of testing was based on the American Heart Association/American College of Cardiology guidelines at the discretion of the supervising cardiologist. These included abnormal hemodynamic response, diagnostic ST-segment changes, significant arrhythmias, chest pain, shortness of breath, and unwillingness or inability of the patient to continue with the test. Hypertensive response to exercise was defined as peak systolic blood pressure during stress test of ≥190 mm Hg in women and ≥210 mm Hg in men.10 Chronotropic incompetence was defined as inability to achieve 85% of the predicted heart rate for a particular age. Predicted heart rate was calculated by 220 minus age. CRF was divided by cutoffs of <6, 6 to 9, 10 to 11, and >11 METs.

Clinical Characteristics

Demographics, body mass index, history of cardiovascular disease, and smoking status were obtained at the time of treadmill testing. Race and sex were self-identified by the patient. Obesity was based on the medical record or self-report. Diabetes mellitus was defined as a prior diagnosis of diabetes mellitus, use of hypoglycemic medications, including insulin, or a database-verified diagnosis of diabetes mellitus. Hypertension was defined as a prior diagnosis of hypertension, use of antihypertensive medications, or a database-verified diagnosis of hypertension. The blood pressure at the time of the test was not used to diagnose hypertension. Dyslipidemia was defined by prior diagnosis of any major lipid abnormality, use of lipid-lowering medications, or a database-verified diagnosis of hypercholesterolemia or dyslipidemia. Known coronary artery disease was defined as prior myocardial infarction, coronary angioplasty, coronary artery bypass surgery, or prior documented obstructive coronary artery disease (CAD) on a previous angiogram.

A family history of CAD was defined as a compatible history in a first-degree relative. A history of smoking was defined as current smoking obtained by self-report at the time of the stress test. Evidence of a sedentary lifestyle was established through a question survey, which asked participants whether they exercised regularly or not. History of active medication use at the time of stress test was obtained by the interviewing registered nurse or exercise physiologist. These medications were categorized into common indications such as antihypertensive medications and lipid-lowering medications. Use of inhaled medications for lung disease was considered a marker of chronic lung disease. By the same token, the use of thyroid medications was presumed to be a marker of underlying thyroid disease. A history of AF was defined as a previous clinical diagnosis of at least paroxysmal AF. Data on risk factors and medication use were supplemented and cross-checked by means of a retrospective search of the electronic medical record, as well as pharmacy claims filed by the patients. Left ventricular ejection fraction reported on echocardiography was also obtained but was available in only a subset of individuals (n=11 089). Left ventricular dysfunction was defined as a left ventricular ejection fraction <50% as measured by 2-dimensional echocardiography in the follow-up period. Risk factors were considered absent when they were reported as such at the time of stress testing or did not meet criteria for a database-verified diagnosis.

Patients with incident CAD were defined as those who were subsequently diagnosed with CAD, that is, a composite of nonfatal myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting. Myocardial infarction and revascularization were ascertained through linkage with administrative claims files from services delivered by the system-affiliated group practice or reimbursed by the system’s health plan. Linkage was performed with the use of appropriate International Classification of Diseases, Ninth Revision (410.xx) codes and Current Procedural Terminology codes for percutaneous coronary intervention (92920–92944) and coronary artery bypass surgery. Data collection and subsequent chart documentation were performed by qualified nursing staff.

Outcome Ascertainment

The primary measured outcome of this study was new-onset AF. This diagnosis was ascertained by linkage with claims files from services delivered by the system-affiliated group practice or reimbursed by the system’s health plan. Linkage was performed by use of the appropriate International Classification of Diseases, Ninth Revision codes (427.31 for AF). A new diagnosis was considered present when the appropriate International Classification of Diseases, Ninth Revision code was identified in ≥3 separate follow-up encounters. Patients who developed isolated atrial flutter were not included in this outcome. International Classification of Diseases, Ninth Revision code 427.31 has been shown to be valid representation of AF (positive predictive value, 70%–95%; median, 79%).8,11

Statistical Analysis

The characteristics of the study population were described at baseline across METs categories. We presented categorical variables as percentages and continuous variables as mean±SD. The trends across categories of METs were evaluated with linear (for continuous variables) or logistic (for categorical variables) regression.

To describe the observed incidence rate of AF across METs categories, we plotted cumulative incidence estimates using the Kaplan-Meier method. We compared differences between the curves using a log-rank test. The number of patients at risk was calculated at different time points. We also plotted 95% confidence intervals (CIs) of the curves. Because competing risk of mortality is a concern, we plotted competing risks of AF and mortality across time.12 We tested differences between curves using the Fine and Gray method.13 Age-, sex-, and race-adjusted probabilities for risk of AF across METs were plotted for the high fitness group (>11 METs) because there is a known concern about a higher risk of AF at higher levels of METs.14

Hazard proportionality was confirmed for key variables via log-log plots and Martingale residuals. Nested Cox proportional hazards models were used to examine the association between peak METs and incident AF.

We adjusted analyses for 3 different models. Model 1 was adjusted for age, sex, and race (white, black, other). Model 2 was adjusted for model 1 covariates and history of hypertension, diabetes mellitus, sedentary habits, obesity, family history of CAD, smoking, hyperlipidemia, known CAD, hypertensive response, and chronotropic incompetence. Model 3 was adjusted for the covariates of model 2 and thyroid medications, digoxin, treated lung disease, β-blocker use, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, calcium channel blocker use, and use of all lipid-lowering medications, including statins. METs were examined as continuous and categorical groups. In addition, we examined the dose-response relationship between METs (as an independent variable) and the risk of AF (as dependent variable) using restricted cubic spline regression adjusted for model 3. Knots were placed at the 5th, 50th, and 95th percentiles of METs (4, 10, and 13 METs, respectively).15,16

We also performed a sensitivity analysis examining the relationship between CRF and AF after adjustment for model 3 covariates and incident CAD as a time-dependent covariate. We also performed 3 subgroup analyses examining the relationship of CRF with AF in individuals who had subsequent left ventricular dysfunction (ejection fraction <50%), in individuals with CRF >10, and in individuals with established CAD (n=8495).

We assessed for effect modification by strata of age (<40, 40–49, 50–59, ≥60 years), sex, race (black, white, other), history of obesity, history of hypertension, history of smoking, history of diabetes mellitus, and history of hyperlipidemia. These findings were presented as a forest plot of hazard ratios (HRs) and 95% CIs. Because the interaction for obesity was significant (P=0.02), we examined the dose-response relationship between METs (as an independent variable) and the risk of AF (as a dependent variable) using restricted cubic spline regression adjusted for model 3 with knots placed at the 5th, 50th, and 95th percentiles of METs in obese and nonobese individuals. All analyses were performed with SAS version 9.3 (SAS Inc, Cary, NC) and the R package for competing risk analysis (R Foundation, Vienna, Austria; download available at http://www.R-project.org).17 Statistical significance was defined as P≤0.05 for main effects and interaction.

Results

The mean age of study participants without AF at baseline was 54±13 years. Compared with adults with excellent fitness (METs >11), adults with poor fitness (METs <6) were more often female (61% versus 20%) and black (40% versus 18%) and more likely to have hypertension (86% versus 44%), diabetes mellitus (33% versus 8%), hyperlipidemia (45 versus 39%), obesity (21% versus 9%), sedentary lifestyle (25% versus 17%), and known CAD (29% versus 5%; P for all <0.001; Table 1). The poor fitness group was less likely to have non-Hispanic whites (56% versus 73%).

Table 1. Baseline Cohort Characteristics by Peak METs

Participants Without Diagnosed AF at Baseline
Characteristic Overall(n=64 561) <6 METs(n=9916) 6–9 METs(n=17 916) 10–11 METs(n=22 810) >11 METs(n=13 919) P Value*
Age, y 54 (13) 65 (12) 58 (12) 52 (11) 46 (10) <0.001
Female, % 46 61 58 46 20 <0.001
Race, %
 White 64 56 60 65 73 <0.001
 Black 29 40 34 27 18 <0.001
 Other 7 4 6 8 9 <0.001
History of hypertension, % 64 86 75 60 44 <0.001
History of hyperlipidemia, % 45 45 49 45 39 <0.001
History of diabetes mellitus, % 19 33 25 16 8 <0.001
Family history of coronary heart disease, % 51 44 50 53 53 <0.001
History of obesity, % 21 21 30 22 9 <0.001
History of current smoking, % 42 40 44 43 38 <0.001
Sedentary lifestyle, % 27 25 33 29 17 <0.001
History of CAD, % 13 29 16 9 5 <0.001
Medications, %
 Hypertension medication 47 71 59 41 24 <0.001
 Calcium channel blocker 14 24 17 11 6
 β-Blocker 21 32 26 18 11 <0.001
 ACE inhibitor 18 23 28 16 9 <0.001
 ARB 3 3 4 3 1 <0.001
 Lipid-lowering medication 23 26 28 22 14 <0.001
 Statin 21 24 26 20 13 <0.001
Treated lung disease, % 9 9 9 7 4 <0.001
Thyroid medication use, % 7 8.8 8.5 6.7 3.5 <0.001
Hypertensive response to exercise, % 23 27 30 22 14 <0.001
Chronotropic incompetence, % 24 51 31 17 7 <0.001
Resting heart rate, bpm 73 (13) 76 (14) 74 (13) 72 (12) 69 (11) 0.03
Resting systolic blood pressure, mm Hg 131 (19) 138 (22) 134 (19) 129 (18) 125 (16) 0.05
Resting diastolic blood pressure, mm Hg 81 (10) 81 (12) 81 (10) 81 (10) 80 (10) 0.001
Peak METs achieved, kcal/kg·h 8.8 (3.1) 4.2 (1.2) 7.0 (0.2) 10.0 (0.1) 13.2 (0.8)

Values are mean (SD) when appropriate. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CAD, coronary artery disease; and MET, metabolic equivalent.

*P values for trends across METs were determined by linear and logistic regression.

Over a median follow-up period of 5.4 years (interquartile range, 2.8–8.6 years), there were 4616 new cases of AF. The unadjusted 5-year cumulative incidence rates of AF across categories of CRF (<6, 6–9, 10–11, and >11 METs) were 18.8%, 9.5%, 5.0%, and 3.7%, respectively. Time-to-event analysis was performed for categories of CRF and risk of AF with the Kaplan-Meier method (log-rank test, P<0.001; Figure 1). To observe competing risk of mortality, adjusted risks of AF and mortality were plotted against time (Figure I in the online-only Data Supplement). The risk curves were significantly different (P<0.001).

Figure 1.

Figure 1. Time-to-event analysis of incident atrial fibrillation by category of metabolic equivalents (METs). The P value was determined by a log-rank test.

In a multivariable Cox regression model adjusted for potential confounders, we found a 7% reduction in the risk of incident AF for every 1 greater MET achieved (HR, 0.93; 95% CI, 0.92–0.94; P<0.001; model 3). The relationships of various categories of CRF with risk of AF are shown in Table 2. The association of model 3 covariates with incident AF is shown in Table I in the online-only Data Supplement.

Table 2. Association Between Peak METs Achieved and Incident AF Among Participants Without a Diagnosis of AF at Baseline (n=64 561)

HR (95% CI), Risk of AF
Model 1* Model 2 Model 3
Per 1-MET increase 0.89 (0.88–0.90) 0.92 (0.91–0.93) 0.93 (0.92–0.94)
P <0.001 <0.001 <0.001
Peak METs
 <6 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 6–9 0.71 (0.66–0.77) 0.80 (0.75–0.87) 0.80 (0.74–0.86)
 10–11 0.47 (0.43–0.51) 0.60 (0.55–0.66) 0.60 (0.54–0.65)
 >11 0.30 (0.27–0.34) 0.44 (0.39–0.50) 0.44 (0.39–0.50)
P for trend <0.001 <0.001 <0.001

AF indicates atrial fibrillation; CI, confidence interval; HR, hazard ratio; and MET, metabolic equivalent.

*Model 1: adjusted for age, sex, and race.

Model 2: model 1 plus history of hypertension, diabetes mellitus, sedentary habits, obesity, family history of coronary artery disease, smoking, hyperlipidemia, hypertensive response, and chronotropic incompetence.

Model 3: model 2 plus thyroid medications, digoxin, treated lung disease, β-blocker use, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, calcium channel blocker use, and use of all lipid-lowering medications, including statins.

In a sensitivity analysis, the relationship of CRF with AF after adjustment for incident CAD as a time-varying covariate in addition to model 3 covariates remained statistically significant (HR, 0.92; 95% CI, 0.91–0.93; P<0.001).

In a subgroup analysis of 2363 patients with left ventricular dysfunction (left ventricular ejection fraction <50%), CRF remained significantly associated with lower risk of AF (HR, 0.96; 95% CI, 0.94–0.99; P=0.01). When the analysis was restricted to only individuals with >10 METs, CRF remained significantly associated with lower risk of AF (HR, 0.94; 95% CI, 0.90–0.98; P=0.001). Findings remained consistent when analyses were restricted to individuals with known cardiovascular disease (Table 3).

Table 3. Association Between Peak METs Achieved and Incident AF Among Participants With History of Known Cardiovascular Disease at Baseline (n=8495)

HR (95% CI), Risk of AF
Model 1* Model 2 Model 3
Per 1-MET increase 0.92 (0.90–0.94) 0.93 (0.91–0.95) 0.94 (0.92–0.96)
P <0.001 <0.001 <0.001
Peak METs
 <6 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 6–9 0.76 (0.67–0.85) 0.79 (0.70–0.90) 0.79 (0.70–0.90)
 10–11 0.65 (0.56–0.75) 0.70 (0.59–0.82) 0.69 (0.59–0.82)
 >11 0.37 (0.28–0.49) 0.43 (0.32–0.57) 0.43 (0.32–0.57)
P for trend <0.001 0.02 0.03

AF indicates atrial fibrillation; CI, confidence interval; HR, hazard ratio; and MET, metabolic equivalent.

*Model 1: adjusted for age, sex, and race.

Model 2: model 1 plus history of hypertension, diabetes mellitus, sedentary habits, obesity, family history of coronary artery disease, smoking, hyperlipidemia, hypertensive response, and chronotropic incompetence.

Model 3: model 2 plus thyroid medications, digoxin, treated lung disease, β-blocker use, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, calcium channel blocker use, and use of all lipid-lowering medications, including statins.

In addition, we assessed for effect modification of the relationship between METs achieved and incident AF by strata of AF risk factors (Figure 2). We found that the magnitude of the inverse association between METs achieved and incident AF was greater for obese individuals. Age, sex, race, history of hypertension, smoking, or diabetes mellitus did not significantly alter the relationship between physical fitness and incident AF.

Figure 2.

Figure 2. Risk of atrial fibrillation associated with baseline peak metabolic equivalents (METs; per 1 MET) within subgroups of the study cohort. CI indicates confidence interval. *All models were adjusted for age, sex, race, history of hypertension, diabetes mellitus, sedentary habits, obesity, family history of coronary artery disease, smoking, hyperlipidemia, hypertensive response, chronotropic incompetence, thyroid medications, digoxin, treated lung disease, β-blocker use, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, calcium channel blocker use, use of all lipid-lowering medications (including statins), and METs. In the age strata, the age variable was replaced with a simplified variable (<40, 40–49, 50–59, ≥60 years).

When cubic spline regression was used to explore the adjusted association between higher levels of CRF and risk of AF, we observed an approximately linear relationship, with HRs significantly >1 for CRF <10 METs (Figure 3). Because there was a significant interaction for obesity, we also examined risk of AF across METs for obese and nonobese individuals in a similar restricted cubic spline model adjusted for model 3 covariates of the Cox model. The plot showed a higher risk of AF for obese individuals at lower METs that rapidly approached and overlapped the risk of AF in nonobese participants at higher levels of METs (Figure II in the online-only Data Supplement).

Figure 3.

Figure 3. Dose-dependent relationship of metabolic equivalents (METs) with risk of atrial fibrillation in an adjusted cubic spline regression model with knots at the 5th, 50th, and 95th percentiles (4, 10, and 13 METs, respectively). *Regression model was adjusted for age, sex, race, history of hypertension, diabetes mellitus, sedentary habits, obesity, family history of coronary artery disease, smoking, hyperlipidemia, hypertensive response, chronotropic incompetence, thyroid medications, digoxin use, treated lung disease, β-blocker use, angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, calcium channel blocker use, use of all lipid-lowering medications (including statins), and METs. Dotted lines represent the upper and lower 95% confidence limits.

We also explored age-, sex-, and race-adjusted predicted probabilities of AF in individuals with METs >10, which demonstrated an almost linear inverse relationship of CRF with AF (Figure III in the online-only Data Supplement).

Discussion

To the best of our knowledge, this is the first large report to examine the association between CRF as measured by exercise treadmill testing and risk of incident AF. In this analysis, we observed that higher levels of CRF were inversely associated with the lower risk of incident AF. We found a substantial dose-response relationship with a 7% lower risk for every 1-MET increase in CRF. This relationship was demonstrated over a median follow-up period of 5.4 years and appeared to be more pronounced in obese and older individuals. In addition, the relationship did not attenuate at higher fitness levels.

CRF is better referred to as a phenotype of physical function and is influenced by factors other than exercise training such as genetics.18 A closely related entity, self-reported physical activity, has been evaluated in many observational studies. In contrast, physical activity represents behavior and may not reflect one’s health such as CRF. Even though there might be fundamental differences between CRF and self-reported physical activity, the present study supports the thought that being fit is inversely associated with incident AF. In the Atherosclerosis Risk in Communities (ARIC) study, 14 219 participants with poor levels of physical activity (<1–149 min/wk of moderate physical activity or 1–74 min/wk of vigorous physical activity) had 1.56 times the risk of AF.19 Similarly, women enrolled in the Women’s Health Initiative (WHI) Study who achieved at least 7.5 MET·h/wk were found to be at a modestly lower risk of AF (HR, 0.86; 95% CI, 0.75–0.98; P=0.03).20 However, this association did not remain significant after adjustment for BMI (a measure of obesity). The authors commented that BMI plays an important role in determining the relationship between physical activity and AF. In our study, the relationship between METS achieved and AF remained significant even after adjustment for obesity.

We found that the inverse association of CRF with AF was stronger in obese patients than nonobese patients. A similar interaction was observed in an analysis from the WHI, in which obese women had a lower risk of AF from increased levels of physical activity.21 Our study has important implications for obese individuals and suggests that obese individuals may potentially benefit by strategies that can improve CRF, provided that CRF is causally associated with AF. There are many plausible mechanisms for this interaction. Obesity is thought to promote AF by increasing left atrial size, which allows the development and propagation of re-entrant electric impulses.22,23 Chronic stretch of pulmonary vein ostia owing to high intracardiac pressures in the obese is known to occur. These ostia act as a nidus for AF and are frequently ablated to cure AF.24 Sleep apnea, which is closely related to obesity, is also an important risk factor for AF. The prevalence of AF in patients with sleep apnea is 6 times higher than that of the general population.25 In a recent meta-analysis of 5 prospective studies, patients with obstructive sleep apnea were at more than twice the risk for AF (odds ratio, 2.38; 95% CI, 1.57–3.62; P<0.001) compared with patients without sleep apnea.26 The mechanism underlying AF in obese patients and patients with sleep apnea is thought to be attributable to increased NADPH oxidase activity and dysfunctional nitric oxide synthase, resulting in increased oxidative stress in the atrial cardiomyocytes and hence AF.27 Increased inflammation that occurs at a result of oxidative stress was also found to be associated with an increased risk of AF.2831 In this study, we observed a greater risk of AF among obese individuals with lower levels of CRF. With increasing levels of CRF, however, this risk gradually declined so that their risk of AF closely approached that of nonobese individuals. The relatively steep decline in AF risk suggests that CRF may be especially important for obese patients, although it must be restated that this is merely a hypothesis-generating analysis that requires further study.

Another important finding in our study was the inverse linear relationship between CRF and AF, which notably did not show evidence of plateauing or reversal at higher levels of CRF. This is contrast to previous studies in which extreme levels of fitness were found to be associated with an increased risk of AF. Indeed, a number of studies have suggested that extreme and sustained exercise likely promotes AF, particularly among elite endurance athletes.32,33 Potential “cardiotoxicity” resulting from excessive participation in endurance exercise has been described by O’Keefe et al.14 Most epidemiological studies, however, have failed to show a higher risk for AF with exercise training in general populations, likely owing to an underrepresentation of highly trained athletes and resultant selection bias.34 The mechanisms explaining the association between exercise and AF have not been fully elucidated, but inflammation, atrial remodeling, and autonomic imbalance are among those most commonly cited.7,3537 These mechanisms do not seem to be important in nonathletes, perhaps because of the less severe hemodynamic changes one would expect with moderate levels of exercise.18 Other potential reasons why we did not observe increased levels of AF among subjects with high levels of CRF may relate to selection bias (because elite athletes are rarely referred for exercise stress testing) and the fact that exercise stress testing is not a form of sustained endurance. These findings are merely exploratory and need further investigation in future studies.

Limitations

The present study has several important limitations. First, incident AF was identified by administrative claims files, which did not include direct evaluation of electrocardiograms. Therefore, a number of persons with undiagnosed AF and those with paroxysmal AF may have been missed as incident cases, attenuating our results. Second, our assessment of baseline physical fitness was based on a single measurement, preventing us from assessing changes in fitness over time or issues related to individual variability. Third, our study population comprised persons referred for stress testing, which undoubtedly carries a greater burden of cardiovascular disease at baseline than the general population and may have led to referral bias. Finally, residual confounding is always a concern with observational studies, especially with covariates assessed via self-report or the medical record rather than direct measurement.

Conclusions

Increased CRF is associated with a lower risk of AF independently of age, sex, or race and other traditional risk factors. This association was strongest in obese patients. This study provides further evidence in support of the benefits of higher overall fitness. Future studies are required to evaluate these findings and to assess whether an increase in fitness is associated with incident AF.

Acknowledgments

We acknowledge Zeina Dardari, MS, for statistical support.

Footnotes

Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.114.014833/-/DC1.

Correspondence to Mouaz H. Al-Mallah, MD, MSc, FACC, FAHA, FESC, Consultant Cardiologist and Division Head, Cardiac Imaging, King Abdul-Aziz Cardiac Center, King Abdul-Aziz Medical City (Riyadh) National Guard Health Affairs, Department Mail Code, 1413, PO Box 22490, Riyadh 11426, Kingdom of Saudi Arabia. E-mail

References

  • 1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA. 2001; 285:2370–2375.CrossrefMedlineGoogle Scholar
  • 2. Gersh BJ, Tsang TS, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications.Trans Am Clin Climatol Assoc. 2004; 115:149–159.MedlineGoogle Scholar
  • 3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.Circulation. 2006; 114:119–125. doi: 10.1161/CIRCULATIONAHA.105.595140.LinkGoogle Scholar
  • 4. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.Circ Cardiovasc Qual Outcomes. 2011; 4:313–320. doi: 10.1161/CIRCOUTCOMES.110.958165.LinkGoogle Scholar
  • 5. Bouzas-Mosquera A, Broullón FJ, Álvarez-García N, Méndez E, Peteiro J, Gándara-Sambade T, Prada O, Mosquera VX, Castro-Beiras A. Left atrial size and risk for all-cause mortality and ischemic stroke.CMAJ. 2011; 183:E657–E664. doi: 10.1503/cmaj.091688.CrossrefMedlineGoogle Scholar
  • 6. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, Vidal B, Scalise A, Tejeira A, Berruezo A, Brugada J ; GIRAFA (Grup Integrat de Recerca en Fibril-lació Auricular) Investigators. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals.Europace. 2008; 10:15–20. doi: 10.1093/europace/eum263.CrossrefMedlineGoogle Scholar
  • 7. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, Rebato C, Elosua R. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study.Europace. 2008; 10:618–623. doi: 10.1093/europace/eun071.CrossrefMedlineGoogle Scholar
  • 8. Al-Mallah MH, Keteyian SJ, Brawner CA, Whelton S, Blaha MJ. Rationale and design of the Henry Ford Exercise Testing Project (the FIT project).Clin Cardiol. 2014; 37:456–461. doi: 10.1002/clc.22302.CrossrefMedlineGoogle Scholar
  • 9. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease.Am Heart J. 1973; 85:546–562.CrossrefMedlineGoogle Scholar
  • 10. Manolio TA, Burke GL, Savage PJ, Sidney S, Gardin JM, Oberman A. Exercise blood pressure response and 5-year risk of elevated blood pressure in a cohort of young adults: the CARDIA study.Am J Hypertens. 1994; 7:234–241.CrossrefMedlineGoogle Scholar
  • 11. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. Identifying atrial fibrillation from electronic medical data: a systematic review.Pharmacoepidemiol Drug Saf. 2012; 21:141–147.CrossrefMedlineGoogle Scholar
  • 12. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks.Biometrics. 1978; 34:541–554.CrossrefMedlineGoogle Scholar
  • 13. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk.Ann Stats. 1988:1141–1154.CrossrefGoogle Scholar
  • 14. O’Keefe JH, Patil HR, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Potential adverse cardiovascular effects from excessive endurance exercise.Mayo Clin Proc. 2012; 87:587–595. doi: 10.1016/j.mayocp.2012.04.005.CrossrefMedlineGoogle Scholar
  • 15. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis.Epidemiology. 1995; 6:356–365.CrossrefMedlineGoogle Scholar
  • 16. Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables.J Clin Epidemiol. 2009; 62:511–7.e1. doi: 10.1016/j.jclinepi.2008.05.015.CrossrefMedlineGoogle Scholar
  • 17. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians.Bone Marrow Transplant. 2007; 40:381–387. doi: 10.1038/sj.bmt.1705727.CrossrefMedlineGoogle Scholar
  • 18. Bouchard C, Daw EW, Rice T, Pérusse L, Gagnon J, Province MA, Leon AS, Rao DC, Skinner JS, Wilmore JH. Familial resemblance for VO2max in the sedentary state: the HERITAGE family study.Med Sci Sports Exerc. 1998; 30:252–258.CrossrefMedlineGoogle Scholar
  • 19. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study.Circ Arrhythm Electrophysiol. 2014; 7:620–625. doi: 10.1161/CIRCEP.113.001244.LinkGoogle Scholar
  • 20. Everett BM, Conen D, Buring JE, Moorthy MV, Lee IM, Albert CM. Physical activity and the risk of incident atrial fibrillation in women.Circ Cardiovasc Qual Outcomes. 2011; 4:321–327. doi: 10.1161/CIRCOUTCOMES.110.951442.LinkGoogle Scholar
  • 21. Azarbal F, Stefanick ML, Salmoirago-Blotcher E, Manson JE, Albert CM, LaMonte MJ, Larson JC, Li W, Martin LW, Nassir R, Garcia L, Assimes TL, Tharp KM, Hlatky MA, Perez MV. Obesity, physical activity, and their interaction in incident atrial fibrillation in postmenopausal women.J Am Heart Assoc. 2014; 3:. doi: 10.1161/JAHA.114.001127.LinkGoogle Scholar
  • 22. Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation.JAMA. 2004; 292:2471–2477. doi: 10.1001/jama.292.20.2471.CrossrefMedlineGoogle Scholar
  • 23. Qureshi W, Soliman EZ, Solomon SD, Alonso A, Arking DE, Shah A, Gupta DK, Wagenknecht LE, Herrington D. Risk factors for atrial fibrillation in patients with normal versus dilated left atrium (from the Atherosclerosis Risk in Communities Study).Am J Cardiol. 2014; 114:1368–1372. doi: 10.1016/j.amjcard.2014.07.073.CrossrefMedlineGoogle Scholar
  • 24. Walters TE, Lee G, Spence S, Larobina M, Atkinson V, Antippa P, Goldblatt J, O’Keefe M, Sanders P, Kistler PM, Kalman JM. Acute atrial stretch results in conduction slowing and complex signals at the pulmonary vein to left atrial junction: insights into the mechanism of pulmonary vein arrhythmogenesis.Circ Arrhythm Electrophysiol. 2014; 7:1189–1197. doi: 10.1161/CIRCEP.114.001894.LinkGoogle Scholar
  • 25. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.Eur Heart J. 2001; 22:1852–1923.CrossrefMedlineGoogle Scholar
  • 26. Qaddoura A, Kabali C, Drew D, van Oosten EM, Michael KA, Redfearn DP, Simpson CS, Baranchuk A. Obstructive sleep apnea as a predictor of atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis.Can J Cardiol. 2014; 30:1516–1522. doi: 10.1016/j.cjca.2014.10.014.CrossrefMedlineGoogle Scholar
  • 27. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation.Circ Res. 2005; 97:629–636. doi: 10.1161/01.RES.0000183735.09871.61.LinkGoogle Scholar
  • 28. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.Circulation. 2014; 130:1847–1858.LinkGoogle Scholar
  • 29. Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, Jones P, Ramprasath VR, O’Hara G, Kopecky S, Brophy JM, Tardif JC ; AFFORD Investigators. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress.J Am Coll Cardiol. 2014; 64:1441–1448. doi: 10.1016/j.jacc.2014.07.956.CrossrefMedlineGoogle Scholar
  • 30. Galassetti P. Inflammation and oxidative stress in obesity, metabolic syndrome, and diabetes.Exp Diabetes Res. 2012; 2012:943706. doi: 10.1155/2012/943706.CrossrefMedlineGoogle Scholar
  • 31. Suzuki K, Ito Y, Ochiai J, Kusuhara Y, Hashimoto S, Tokudome S, Kojima M, Wakai K, Toyoshima H, Tamakoshi K, Watanabe Y, Hayakawa N, Maruta M, Watanabe M, Kato K, Ohta Y, Tamakoshi A ; JACC Study Group. Relationship between obesity and serum markers of oxidative stress and inflammation in Japanese.Asian Pac J Cancer Prev. 2003; 4:259–266.MedlineGoogle Scholar
  • 32. Myrstad M, Nystad W, Graff-Iversen S, Thelle DS, Stigum H, Aarønæs M, Ranhoff AH. Effect of years of endurance exercise on risk of atrial fibrillation and atrial flutter.Am J Cardiol. 2014; 114:1229–1233. doi: 10.1016/j.amjcard.2014.07.047.CrossrefMedlineGoogle Scholar
  • 33. Guasch E, Nattel S. CrossTalk proposal: prolonged intense exercise training does lead to myocardial damage.J Physiol. 2013; 591(pt 20):4939–4941. doi: 10.1113/jphysiol.2013.257238.CrossrefMedlineGoogle Scholar
  • 34. Ofman P, Khawaja O, Rahilly-Tierney CR, Peralta A, Hoffmeister P, Reynolds MR, Gaziano JM, Djousse L. Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysis.Circ Arrhythm Electrophysiol. 2013; 6:252–256. doi: 10.1161/CIRCEP.113.000147.LinkGoogle Scholar
  • 35. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter.Europace. 2009; 11:11–17. doi: 10.1093/europace/eun289.CrossrefMedlineGoogle Scholar
  • 36. Wilhelm M, Nuoffer JM, Schmid JP, Wilhelm I, Saner H. Comparison of pro-atrial natriuretic peptide and atrial remodeling in marathon versus non-marathon runners.Am J Cardiol. 2012; 109:1060–1065. doi: 10.1016/j.amjcard.2011.11.039.CrossrefMedlineGoogle Scholar
  • 37. Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid JP, Saner H. Atrial remodeling, autonomic tone, and lifetime training hours in nonelite athletes.Am J Cardiol. 2011; 108:580–585. doi: 10.1016/j.amjcard.2011.03.086.CrossrefMedlineGoogle Scholar

CLINICAL PERSPECTIVE

Atrial fibrillation (AF) is an increasingly prevalent condition. Fitness has been shown to be associated with a lower risk of a number of cardiovascular diseases. However, few studies have assessed whether higher fitness is associated with a lower risk of AF. Using a diverse population of >64 000 patients, we establish that fitness has a strong, inverse association with incident AF. Fitness was even more inversely associated with AF among obese patients. This study establishes fitness as an independent risk factor of AF and further raises the question of whether improving one’s fitness might help prevent AF, an important question for subsequent research.

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.